Company intelligence
Greywolf Therapeutics
The clinical-stage biotech company advancing novel antigen modulation treatments for cancer and autoimmune diseases.
About Greywolf Therapeutics
Many diseases are caused, or resist treatment, because T cells can't recognize or target cells correctly. Our first-in-class small molecules are developed to control T cell activation by modulating antigen presentation, altering how cells appear to the immune system so it can recognize and target them correctly. Our oncology treatment (GRWD5769) is delivering promising Phase 1/2 data in patients with solid tumors, demonstrating a strong safety and tolerability profile, as well as generating meaningful clinical activity. Our autoimmunity treatment (GRWD0715) is progressing in a Phase 1/2 trial to treat the source of axial spondyloarthritis ahead of a planned expansion into other autoimmune indications. Greywolf is headquartered in Oxford, UK.
Verified activity
Signals from Greywolf Therapeutics
5 published signals
Products & Services
Greywolf Therapeutics dosed GRWD0715, its first-in-class oral ERAP1 inhibitor, in the first participants with axial spondyloarthritis.
Reported by Greywolf Therapeutics
Partnerships
Greywolf Therapeutics continues to inform a planned expansion into a broad range of autoimmune diseases by identifying ERAP-associated indications, including IBD and psoriatic arthritis.
Reported by Greywolf Therapeutics
Legal & Regulatory
Greywolf Therapeutics secured US composition-of-matter patent protection for GRWD0715.
Reported by Greywolf Therapeutics
Products & Services
Greywolf Therapeutics is offering a completely novel therapy for patients that could truly change lives.
Reported by Kate Anderton
Research & Knowledge
Greywolf Therapeutics delivered the study to this point and is now enrolling and dosing participants as they continue to explore new treatment options for people living with axSpA.
Reported by Charlotte O'Connor